Compare BLLN & MMS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BLLN | MMS |
|---|---|---|
| Founded | 2016 | 1975 |
| Country | United States | United States |
| Employees | 713 | N/A |
| Industry | Medical Specialities | Business Services |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.9B | 3.6B |
| IPO Year | N/A | 1997 |
| Metric | BLLN | MMS |
|---|---|---|
| Price | $83.95 | $59.43 |
| Analyst Decision | Buy | |
| Analyst Count | 7 | 0 |
| Target Price | ★ $126.71 | N/A |
| AVG Volume (30 Days) | 575.7K | ★ 718.9K |
| Earning Date | 05-06-2026 | 05-07-2026 |
| Dividend Yield | N/A | ★ 2.02% |
| EPS Growth | N/A | ★ 10.42 |
| EPS | N/A | ★ 3.50 |
| Revenue | N/A | ★ $2,392,236,000.00 |
| Revenue This Year | $46.29 | $0.44 |
| Revenue Next Year | $30.14 | $5.15 |
| P/E Ratio | ★ N/A | $17.18 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $61.96 | $57.32 |
| 52 Week High | $138.70 | $100.00 |
| Indicator | BLLN | MMS |
|---|---|---|
| Relative Strength Index (RSI) | 49.23 | 29.64 |
| Support Level | $79.33 | N/A |
| Resistance Level | $97.36 | $70.49 |
| Average True Range (ATR) | 8.45 | 2.56 |
| MACD | 0.37 | -0.53 |
| Stochastic Oscillator | 35.65 | 13.15 |
BillionToOne Inc is a molecular diagnostics company. It offers a portfolio of ultrasensitive tests covering prenatal genetic testing, cancer therapy selection, and response monitoring, which are based on its Quantitative Counting Templates (QCT) molecular counting platform. The company's product portfolio comprises UNITY, a portfolio of prenatal testing products that can conduct fetal risk analysis without requiring a paternal sample; Northstar Select, a ultrasensitive liquid biopsy test that provides insights into appropriate therapies for stage III or IV cancer patients; and Northstar Response, a tissue-free, pan-cancer, liquid biopsy test that measures several genomic loci uniquely methylated in cancer to provide insight into dynamic changes in therapy response.
Maximus Inc designs, develops, and delivers programs enabling people to access vital government services. It translates health and human services public policy into operating models that achieve outcomes for governments at scale. The company covers a broad array of services, including the operation of large health insurance eligibility and enrollment programs; clinical services, including assessments, appeals, and independent medical reviews; and technology services. The company operates through the following segments: U.S. Federal Services, U.S. Services, and Outside the U.S. A majority of its revenue is derived from the U.S. Federal Services segment, which engages with various U.S. federal government agencies to deliver clinical services, maintenance services, and technology solutions.